Objective To investigate the effect of nerve growth factor(NGF)in the process of muscular neurotization of denerva- ted vascularized skeletal muscle.Method By using NGF(0.5 ?g/d) to transplanted skeletal muscle,muscular neurotization was exa- mined with histological,histochemical,electron microscope and immunohistochemical methods at various time.Result NGF was effective in promoting muscular neurotization and diminishing denervated muscle atrophy in grafted denervated skeletal muscle.Conclusion NGF can promote the muscular neurotization and diminish denervated muscle atrophy.

Humans ; Protein Kinase Inhibitors ; therapeutic use ; Protein-Tyrosine Kinases ; antagonists & inhibitors

Adolescent ; Dermatitis Herpetiformis ; complications ; Esophageal Diseases ; etiology ; Humans ; Male ; Mucous Membrane ; pathology

Antibodies, Anticardiolipin ; blood ; Autoantibodies ; blood ; Child ; Child, Preschool ; Female ; Humans ; Infant ; Male ; Mucocutaneous Lymph Node Syndrome ; immunology ; beta 2-Glycoprotein I ; immunology

Combined Modality Therapy ; Head and Neck Neoplasms ; drug therapy ; pathology ; radiotherapy ; surgery ; Humans ; Hypopharyngeal Neoplasms ; radiotherapy ; surgery ; Medical Oncology ; education ; Nasopharyngeal Neoplasms ; radiotherapy ; surgery ; Neoplasm Staging ; Otorhinolaryngologic Surgical Procedures ; education

Combined Modality Therapy ; Consensus ; Head and Neck Neoplasms ; therapy ; Humans

Combined Modality Therapy ; Follow-Up Studies ; Head and Neck Neoplasms ; diagnosis ; epidemiology ; therapy ; Humans ; Quality of Life ; Specialization

Objective:To evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) in CHOP regimen for un-treated elderly patients with advanced diffuse large B-cell lymphoma (DLBCL). Methods:In a prospective phase II study, we analyzed the feasibility of PLD-modified CHOP regimen in elderly patients with advanced stages of DLBCL. PLD was administered at 30 mg/m2 in combination with cyclophosphamide, vincristine, and prednisone at standard doses every 21 d for six cycles. CD20 positive patients were given option for rituximab treatment. Results:From November 2011 to March 2014, 30 patients with a median age of 70 years (range:63 to 80) were enrolled in this study. Up to 24 cases (80.0%) obtained an International Prognostic Index of≥3. The overall re-sponse rate was 86.7%, and the complete remission rate was 66.7%. With a median follow-up of 20.1 months, the 18-month overall and progression-free survival rates were 82.4%and 70.1%, respectively. The main toxicity was neutropenia, reaching grades 3 to 4 in the 24 cases (80.0%). No significant changes existed in patients' left ventricular ejection fraction and serum troponin-T during the study. Four patients (13.3%) showed asymptomatic abnormal changes in electrocardiogram after PLD infusion. Conclusion:CHOP regimen with PLD is an effective alternative for the treatment of DLBCL in elderly patients, exhibiting an acceptable toxicity.

Comparing the patients with type 2 diabetes and the control and using the animal models,the researchers have found some disease related proteins and the marks for disease detection.They have set some new detection methods and give us a special view into type 2 diabetes.We do some primary discussions about recent studies and future development directions in the proteomics study of type 2 diabetes in this article.

Carcinoma, Squamous Cell ; pathology ; surgery ; Head and Neck Neoplasms ; pathology ; surgery ; Humans ; Lymph Nodes ; pathology ; surgery ; Lymphatic Metastasis ; Minimally Invasive Surgical Procedures ; methods ; Neck ; Neck Dissection ; methods ; Neoplasm Staging